Variability in Urate-lowering Therapy Prescribing: A Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) Physician Survey

Gout and Crystal Arthritis Network, University of Otago, Christchurch, New Zealand; University of Otago, Wellington, New Zealand; University of Alabama at Birmingham, Birmingham, Alabama, USA. The authors acknowledge the support of the Gout, Hyperuricemia and Crystal-Associated Disease Network. Address correspondence to Prof. L. Stamp, Department of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch 8140, New Zealand. Email: Lisa.Stamp@cdhb.health.nz.

Gout and Crystal Arthritis Network, University of Otago, Christchurch, New Zealand; University of Otago, Wellington, New Zealand; University of Alabama at Birmingham, Birmingham, Alabama, USA. The authors acknowledge the support of the Gout, Hyperuricemia and Crystal-Associated Disease Network. Address correspondence to Prof. L. Stamp, Department of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch 8140, New Zealand. Email: Lisa.Stamp@cdhb.health.nz.

Gout and Crystal Arthritis Network, University of Otago, Christchurch, New Zealand; University of Otago, Wellington, New Zealand; University of Alabama at Birmingham, Birmingham, Alabama, USA. The authors acknowledge the support of the Gout, Hyperuricemia and Crystal-Associated Disease Network. Address correspondence to Prof. L. Stamp, Department of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch 8140, New Zealand. Email: Lisa.Stamp@cdhb.health.nz.